Stuart D Shumway

Summary

Affiliation: Merck Research Laboratories
Country: USA

Publications

  1. pmc Unique functions of CHK1 and WEE1 underlie synergistic anti-tumor activity upon pharmacologic inhibition
    Amy D Guertin
    Department of Oncology, Merck Research Laboratories, 33 Avenue Louis Pasteur, Boston, MA 02115, USA
    Cancer Cell Int 12:45. 2012
  2. doi request reprint Preclinical evaluation of the WEE1 inhibitor MK-1775 as single-agent anticancer therapy
    Amy D Guertin
    Oncology Biology, Merck Research Laboratories, Boston, MA, USA
    Mol Cancer Ther 12:1442-52. 2013

Collaborators

  • Jing Li
  • Yaping Liu
  • Nathan R Miselis
  • Amy D Guertin
  • Yair Benita
  • Carlo Toniatti
  • Igor Feldman
  • Leigh Zawel
  • Brian Long
  • Alwin G Schuller
  • Melissa S Hurd
  • Stephen E Fawell
  • D Gary Gilliland
  • Heather A Hirsch
  • Xianlu Qu
  • Andrew Bloecher
  • Melissa Hurd
  • Melissa M Martin
  • Brian Roberts

Detail Information

Publications2

  1. pmc Unique functions of CHK1 and WEE1 underlie synergistic anti-tumor activity upon pharmacologic inhibition
    Amy D Guertin
    Department of Oncology, Merck Research Laboratories, 33 Avenue Louis Pasteur, Boston, MA 02115, USA
    Cancer Cell Int 12:45. 2012
    ..abstract:..
  2. doi request reprint Preclinical evaluation of the WEE1 inhibitor MK-1775 as single-agent anticancer therapy
    Amy D Guertin
    Oncology Biology, Merck Research Laboratories, Boston, MA, USA
    Mol Cancer Ther 12:1442-52. 2013
    ..Our findings provide rationale for WEE1 inhibition as a potent anticancer therapy independent of a genotoxic partner and suggest that low PKMYT1 expression could serve as an enrichment biomarker for MK-1775 sensitivity...